查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1862944

基於腫瘤學的體內CRO市場（按動物模型、給藥途徑、治療方法和最終用戶分類）－2025-2032年全球預測

Oncology Based In-Vivo CRO Market by Animal Model, Route Of Administration, Therapeutic Modality, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，腫瘤體內 CRO 市場將成長至 34.3 億美元，複合年成長率為 11.75%。

主要市場統計數據
基準年 2024 14.1億美元
預計年份：2025年 15.7億美元
預測年份：2032年 34.3億美元
複合年成長率 (%) 11.75%

明確腫瘤領域體內研究的策略要務，以加速轉化突破、降低研究失敗率並加強相關人員的臨床前決策。

癌症研究領域依然複雜多變，經營團隊需要簡潔明了、切實可行的洞察，才能做出直接影響後續臨床結果的臨床前決策。本執行摘要整合了營運、科學和策略觀點，闡明了體內研究能力在哪些方面最為重要，實驗設計選擇如何影響轉化應用，以及應指導服務和夥伴關係投資的組織優先事項。

免疫工程、精準模型、整合分析和協作生態系統驅動的不斷發展的臨床前範式正在重塑腫瘤體內研究實踐。

臨床前研究環境正在經歷變革性變化，改變癌症計畫的規劃和實施方式。免疫工程的進步以及人源化和基因定義的動物模型的成熟，提高了實驗機制的可重複性。同時，包括機器學習驅動的影像分析和生物標記縱向追蹤在內的綜合分析技術，正在將複雜的體內數據轉化為清晰、可操作的指標。這些技術進步也正在推動組織變革。發現、轉化和臨床團隊之間的緊密合作，使得臨床相關終點能夠更早達成共識。

評估新興貿易壁壘對腫瘤領域體內測試服務提供和全球研究連續性營運成本、監管和創新的連鎖影響

新的貿易政策和關稅制度除了直接增加採購成本外，還會產生複雜的後續影響。對進口試劑、特殊動物品系和關鍵設備徵收更高的關稅，並加強海關審查，會導致採購時間延長、供應鏈分散以及庫存維修成本增加。實際上，這些營運上的摩擦會直接導致研究啟動延遲、實驗週期縮短以及尋找替代供應來源的困難，從而降低癌症計畫進度安排的可預測性。

分析模型選擇、給藥途徑、治療方法和最終用戶細分，以揭示體內腫瘤學中細微的需求促進因素及其對實驗設計的影響。

清晰的細分觀點能夠明確科學和商業性優先事項的分歧所在，並指導如何根據實驗目標最佳化資源分配。以動物模型分類，研究通常分為鼠類和非鼠類兩類。鼠類模型包括基因工程小鼠模型、免疫功能健全的同基因小鼠模型和小鼠異種移植模型，而非鼠類模型則包含犬、兔子和大鼠模型。每類模型在免疫學、藥理學和毒理學終點方面各有優勢，這些優勢直接指導研究設計決策和供應商選擇。因此，專案經理必須使模型選擇與作用機制和感興趣的轉化研究問題相符。

區域比較分析突顯了世界各地腫瘤研究中心在策略重點、供應鏈實踐、監管環境和合作機會方面的差異。

區域趨勢影響著能力的建構方式、供應鏈的結構以及科學合作的活躍程度。在美洲，轉化醫學專長的集中、強大的生物技術生態系統以及完善的腫瘤免疫學基礎設施，促進了高通量、以轉化醫學為導向的體內研究項目的發展，這些項目需要快速迭代並與臨床研發管線緊密銜接。該地區的監管能力和活躍的創業投資活動支持申辦方和服務供應商之間的靈活夥伴關係，同時也強調了可重複性和文件記錄的重要性。

服務供應商之間的競爭定位和能力差異化可能會專注於專業動物模型、技術整合、資訊服務和策略聯盟。

腫瘤領域體內試驗的競爭格局日益凸顯，其關鍵在於服務能力的廣度、專業知識的深度以及將資訊服務與濕實驗室操作相結合的能力。能夠同時擁有先進的小鼠模型、檢驗的非小鼠毒理學平台以及嚴謹的給藥途徑專業知識的服務商，可以為轉化醫學計畫提供差異化的端到端解決方案。同樣重要的是，服務商還需具備滿足特定治療方式需求的能力，例如免疫查核點抑制劑的免疫治療終點檢測，以及激酶抑制劑和小分子藥物的藥物動力學和標靶結合檢測。

為領導者提供切實可行的策略建議，以增強營運韌性、優先考慮科學投資並加速臨床前腫瘤學計畫的轉化價值。

產業領導者應採取多管齊下的策略方法，在充分利用科學進步的同時，確保業務連續性。首先，應實現採購和庫存策略多元化，以降低動物品系、特殊試劑和關鍵設備等單一故障點所帶來的風險。建立檢驗的替代供應商並維持關鍵組件的滾動庫存，有助於即使在外部貿易和物流中斷的情況下也能維持測試計劃的進行。其次，應優先投資於反映治療重點領域的模型組合。例如，應保持基因工程小鼠模型、免疫功能健全的同基因移植系統和關鍵的非小鼠毒理學模型之間的平衡組合，以應對各種轉化醫學挑戰。

結合關鍵相關人員的見解、實驗室檢驗、營運審核和精心挑選的二手證據，採用穩健的三角測量方法，可確保得出嚴謹且可操作的結論。

本執行摘要的調查方法結合了定性一手調查、有針對性的營運檢驗以及精心挑選的二手證據，以確保研究結果嚴謹且具有直接適用性。關鍵投入包括對資深轉換科學家、營運負責人和採購專家進行結構化訪談，以收集關於模型選擇、供應商績效和物流挑戰的第一手資訊。此外，還輔以營運審核和實驗室訪問，以檢驗工作流程、模型培育計劃和資料收集流程，從而對報告的能力進行實地驗證。

明確總結營運洞察、科學趨勢和戰略意義，以指導業務決策並最佳化腫瘤學領域的近期研究計劃。

這種整合凸顯了臨床前腫瘤學研究中的幾個永恆真理：模型選擇至關重要，運作韌性支撐著轉化研究的可靠性，而整合的資料實踐則縮短了從實驗中觀察到專案決策的流程。免疫腫瘤學和標靶治療的科學進步需要與作用機制、給藥途徑和臨床終點相匹配的專門體內策略。同時，從貿易措施到區域監管差異等外部壓力，都要求申辦方和提供者投資於採購多元化、建立在地化能力以及加強合約框架。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 擴展人源化小鼠模型，用於對需要複雜T細胞交互作用的免疫腫瘤療法進行臨床前評估。
  • 整合先進的體內顯微鏡和PET/MRI成像技術，以增強體內模型中腫瘤進展和藥物分佈的即時研究
  • 引入基於 CRISPR/Cas9 的腫瘤模型可加速腫瘤學領域體內研究的標靶檢驗和功能基因組學分析。
  • 透過引入反映不同腫瘤異質性的患者來源異種移植模型（PDX），實現個人化癌症治療測試策略
  • 利用高性能體內篩檢平台加速先導化合物，縮短新藥臨床試驗申請（IND）提交時間
  • 為滿足日益成長的符合監管標準的腫瘤數據需求，亞太地區正在擴大符合GLP規範的體內CRO設施。

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 基於動物模型的腫瘤體內CRO市場

  • 老鼠
    • 基因工程小鼠模型
    • 免疫功能健全的同基因模型
    • 小鼠異種移植模型
  • 非滑鼠
    • 狗
    • 兔子
    • 鼠

9. 依給藥管道分類的腫瘤體內CRO市場

  • 靜脈
  • 口服
  • 皮下

10.治療方法領域體內CRO市場

  • 化療
  • 免疫療法
    • 查核點抑制劑
    • 單株抗體
  • 標靶治療
    • 激酶抑制劑
    • 小分子抑制劑

11. 依最終用戶分類的腫瘤體內CRO市場

  • 學術和研究機構
  • 合約研究組織
  • 製藥公司

12. 各地區腫瘤體內CRO市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

13. 腫瘤體內CRO市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各國腫瘤體內CRO市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Charles River Laboratories International, Inc.
    • Laboratory Corporation of America Holdings
    • WuXi AppTec Co., Ltd.
    • Inotiv, Inc.
    • Crown Bioscience, Inc.
    • Taconic Biosciences, Inc.
    • Pharmaron（Group）Co., Ltd.
    • Explora BioLabs, Inc.
    • GenScript ProBio Co., Ltd.
    • Oncodesign SA
Product Code: MRR-FF012EDC38C0

The Oncology Based In-Vivo CRO Market is projected to grow by USD 3.43 billion at a CAGR of 11.75% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.41 billion
Estimated Year [2025] USD 1.57 billion
Forecast Year [2032] USD 3.43 billion
CAGR (%) 11.75%

Framing the strategic imperative for oncology in-vivo research to accelerate translational breakthroughs, reduce attrition, and strengthen preclinical decision-making across stakeholders

The landscape of oncology research remains complex and dynamic, and executives require concise, actionable intelligence to make preclinical decisions that directly influence downstream clinical outcomes. This executive summary synthesizes operational, scientific, and strategic perspectives to clarify where in-vivo capabilities matter most, how experimental design choices shape translational relevance, and which organizational priorities should guide investment in services and partnerships.

Throughout the report, emphasis is placed on the intersection between scientific rigor and operational resilience. Translational value depends not only on model selection and dosing paradigms but also on supply chain integrity, data fidelity, and regulatory alignment. Consequently, the executive view focuses on practical levers that reduce technical attrition, accelerate validation timelines, and improve reproducibility across multicenter programs. By concentrating on decision points that executives can influence-such as model portfolios, vendor qualification, and integrated data pipelines-this introduction sets the stage for a pragmatic, strategy-forward conversation that informs both near-term actions and medium-term capability building.

The intent is to equip decision-makers with a clear framework for aligning scientific priorities with commercial realities and operational constraints, thereby enabling more predictable and effective progression from preclinical insights to clinical hypotheses.

Evolving preclinical paradigms driven by immunoengineering, precision models, integrated analytics, and collaborative ecosystems that are reshaping oncology in-vivo research practices

The preclinical research environment has been undergoing transformative shifts that are changing how oncology programs are designed and executed. Advances in immunoengineering and the maturation of humanized and genetically defined animal models are improving the mechanistic fidelity of experiments. At the same time, integrated analytics, including machine learning-enabled image analysis and longitudinal biomarker tracking, are turning complex in-vivo datasets into clearer go/no-go signals. These technological evolutions are accompanied by organizational shifts: tighter collaboration between discovery, translational, and clinical teams is enabling earlier alignment on endpoints that matter clinically.

Concurrently, the industry is seeing methodological convergence between in-vivo and ex vivo approaches. Organoid systems and sophisticated co-culture platforms are increasingly used to triage candidates before committing to resource-intensive animal studies, thereby creating a cascade effect that raises the bar for the in-vivo experiments that are performed. Regulatory expectations and reproducibility imperatives are also prompting greater standardization of protocols and metadata capture, leading providers to invest in quality systems and data harmonization. Together, these shifts are not merely incremental; they are reshaping service offerings, partnership models, and the criteria by which translational success is judged.

Assessing the cascading operational, cost, regulatory, and innovation effects of emerging trade barriers on oncology in-vivo service delivery and global research continuity

Emerging trade policies and tariff regimes have introduced a complex set of downstream effects that extend beyond immediate procurement costs. Increased duties and customs scrutiny for imported reagents, specialized animal strains, and critical equipment can lead to longer lead times, fragmented supply chains, and higher inventory carrying costs. In practice, these operational frictions often translate into delayed study starts, compressed experiment windows, and the need for contingency sourcing, all of which erode schedule predictability for oncology programs.

Further, tariffs can alter vendor economics and sourcing decisions, prompting some providers to localize certain functions or to reconfigure service portfolios to rely less on imported components. This reconfiguration can have knock-on effects for model availability, especially for specialized or proprietary strains that are produced in geographically concentrated facilities. In turn, sponsors and service providers face a choice between maintaining tight biological fidelity through original model use or accepting alternative models that may introduce translational risk.

Importantly, the cumulative impact of trade measures also affects collaborative research that depends on cross-border sample transfers or multinational study coordination. To maintain momentum, research leaders must prioritize supply chain transparency, diversify vendor relationships, and incorporate contingency planning into project timelines. When combined with improved forecasting and contractual flexibility, such measures help mitigate the operational uncertainty introduced by evolving tariff environments.

Dissecting model selection, administration routes, therapeutic modalities, and end user segmentation to reveal nuanced demand drivers and experimental design implications for in-vivo oncology

A robust segmentation lens clarifies where scientific and commercial priorities diverge, and how resource allocation should be tailored to experimental intent. When examined by animal model, studies are commonly categorized into murine and non-murine groups; murine models include genetically engineered mouse models, immunocompetent syngeneic models, and mouse xenografts, while non-murine options encompass dog, rabbit, and rat models. Each of these model classes has different strengths for immunology, pharmacology, and toxicology endpoints, which directly guides study design decisions and vendor selection. Thus, portfolio managers should align model choice with the mechanism of action and the translational questions at hand.

Route of administration segmentation-typically intravenous, oral, and subcutaneous-further refines experimental planning. Dosing route influences pharmacokinetics, formulation strategies, and safety assessment, and therefore it must be considered early in preclinical development to ensure clinically relevant exposure. Therapeutic modality segmentation delineates distinct developmental pathways: chemotherapy, immunotherapy, and targeted therapy; within immunotherapy, checkpoint inhibitors and monoclonal antibodies are principal subcategories, and within targeted therapy, kinase inhibitors and small molecule inhibitors define technical approaches. These modality distinctions have operational implications for dosing regimens, biomarker selection, and model suitability.

Finally, end user segmentation-covering academia and research institutes, contract research organizations, and pharmaceutical companies-reveals differing expectations around throughput, documentation rigor, and customization. Academic customers often prioritize exploratory endpoints and method development, whereas pharmaceutical sponsors emphasize regulatory readiness and data traceability. Contract research organizations occupy an intermediary role, balancing standardization with bespoke services to serve both academic and industry clients. Together, these segmentation dimensions create a matrix that should inform capability investments, pricing strategies, and partnership models.

Comparative regional dynamics highlighting distinct strategic priorities, supply chain realities, regulatory landscapes, and collaborative opportunities across global oncology research hubs

Regional dynamics shape how capabilities are developed, how supply chains are structured, and where scientific collaboration is most active. In the Americas, there is a concentration of translational expertise, strong biotech ecosystems, and established infrastructure for immuno-oncology, which encourages high-throughput, translationally focused in-vivo programs that demand rapid iteration and close integration with clinical pipelines. This region's regulatory familiarity and dense venture capital activity support agile partnerships between sponsors and service providers, yet it also places a premium on reproducibility and documentation practices.

In Europe, Middle East & Africa, variations in regulatory frameworks and research funding models create heterogeneity in capability and demand. Institutional collaborations and multi-center academic networks often drive innovation here, and providers frequently need to accommodate a broader spectrum of compliance requirements and language-specific documentation. Supply chain considerations can vary significantly across countries, making regional logistics expertise and local inventory strategies important for maintaining timelines.

Asia-Pacific is characterized by fast-growing research capacity, increasing domestic pharmaceutical R&D, and a rising share of outsourced preclinical work. This region offers opportunities for cost-effective operations, access to diverse biological models, and expanding laboratory infrastructure. However, leaders must navigate differing regulatory expectations, local ethical standards, and the need for robust quality management systems to ensure data generated locally is acceptable to multinational sponsors. Altogether, regional distinctions influence how providers prioritize investments and how sponsors allocate studies to maximize both scientific validity and operational efficiency.

Competitive positioning and capability differentiation among service providers emphasizing specialized animal models, technology integration, data services, and strategic alliances

Competitive dynamics in the oncology in-vivo space are increasingly defined by capability breadth, specialization depth, and the ability to integrate data services with wet-lab operations. Providers that combine access to advanced murine models, validated non-murine toxicology platforms, and rigorous route-of-administration expertise can offer differentiated end-to-end solutions for translational programs. Equally important is the capacity to support modality-specific needs, such as immunotherapy endpoint assays for checkpoint inhibitors or pharmacokinetic and target engagement assays for kinase inhibitors and small molecule programs.

Beyond technical offerings, leading firms are investing in standardized reporting, electronic data capture, and analytics platforms that translate raw experimental outputs into decision-ready intelligence. Strategic alliances and co-development arrangements with discovery organizations are also shaping the competitive landscape, enabling providers to participate earlier in candidate selection and to influence preclinical strategy. Service differentiation is furthermore influenced by geographical reach and supply chain robustness; providers with localized breeding facilities, decentralized reagent sourcing, and clear export/import expertise are more resilient to operational shocks.

Intellectual property considerations and the emergence of specialized contract service verticals-such as immuno-oncology platforms or precision oncology models-create niches that smaller, highly specialized providers can exploit. For sponsors, selecting a partner increasingly involves assessing both technical fit and the provider's ability to adapt protocols, share data transparently, and align around development timelines.

Actionable strategic recommendations for leaders to build operational resilience, prioritize scientific investments, and accelerate translational value from preclinical oncology programs

Industry leaders should adopt a multi-pronged strategic approach to capitalize on scientific advances while safeguarding operational continuity. First, diversify sourcing and inventory strategies to reduce exposure to single-point failures in animal strains, specialized reagents, and critical equipment. Building validated alternative suppliers and maintaining rolling inventory for key components will preserve study schedules when external trade or logistics disruptions occur. Second, prioritize investment in model portfolios that reflect therapeutic focus areas; for example, retain a balanced mix of genetically engineered mouse models, immunocompetent syngeneic systems, and key non-murine toxicology models to cover a broad spectrum of translational questions.

Third, integrate data management and analytics capabilities with laboratory operations to ensure high-quality metadata capture, reproducible protocols, and rapid downstream analysis. Establishing common data standards across internal and external partners reduces ambiguity in interpretation and accelerates decision cycles. Fourth, engage proactively with regulatory and ethical bodies to harmonize expectations for study design, humane use of animals, and data transparency; early engagement mitigates rework and supports cross-border acceptability of data. Finally, invest in talent development and cross-functional teams that bridge discovery, translational science, and operations so that experimental design decisions are aligned with program objectives and commercial imperatives.

Taken together, these measures create a resilient, scientifically robust platform that supports faster, more reliable translation of preclinical findings into clinical investigation.

Robust triangulation approach combining primary stakeholder intelligence, laboratory validations, operational audits, and curated secondary evidence to ensure rigorous actionable conclusions

The research methodology underpinning this executive synthesis combines qualitative primary engagement, targeted operational validation, and curated secondary evidence to ensure findings are both rigorous and directly applicable. Primary inputs included structured interviews with senior translational scientists, operational leaders, and procurement specialists to capture first-hand perspectives on model selection, vendor performance, and logistics challenges. These interviews were complemented by operational audits and lab visits that validated workflows, model breeding programs, and data capture processes, providing on-the-ground confirmation of reported capabilities.

Secondary evidence was assembled from open literature, technical white papers, and regulatory guidance documents to contextualize technological trends and evolving best practices. To ensure reliability, findings were triangulated across multiple sources and checked for internal consistency; where divergent perspectives emerged, follow-up queries were used to reconcile differences and to clarify the operational implications. Quality control procedures included protocol traceability checks, verification of assay validation status, and assessment of data management practices to confirm reproducibility claims.

By combining stakeholder insight with empirical validation and documentary review, the methodology balances depth and breadth, resulting in conclusions that are both evidence-based and pragmatic for decision-makers.

Clear conclusions synthesizing operational insights, scientific trends, and strategic implications to guide executive decision-making and near term research program optimization in oncology

This synthesis brings into focus several enduring truths for preclinical oncology research: model choice matters, operational resilience underwrites translational confidence, and integrated data practices shorten the path from experimental observation to program decision. Scientific progress in immuno-oncology and targeted therapeutics demands tailored in-vivo strategies that reflect mechanism of action, dosing route, and clinical endpoints. At the same time, external pressures-ranging from trade measures to regional regulatory variation-require that sponsors and providers alike invest in diversified sourcing, localized capabilities, and stronger contractual frameworks.

Looking ahead, organizations that harmonize scientific rigor with operational discipline will be best positioned to de-risk early development and to deliver reproducible, clinically meaningful data. This requires a sustained focus on capability building, cross-functional alignment, and strategic partnerships that enable earlier access to translational expertise. Ultimately, the combination of advanced model systems, robust quality systems, and analytics that produce decision-ready outputs will determine which programs advance with confidence and which require further iteration.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of humanized mouse models for preclinical assessment of immuno-oncology therapies requiring complex T-cell interactions
  • 5.2. Integration of advanced intravital microscopy and PET/MRI imaging to enhance real-time tumor progression and drug distribution studies in in-vivo models
  • 5.3. Adoption of CRISPR/Cas9-engineered tumor models to accelerate target validation and functional genomics in oncology in-vivo research
  • 5.4. Implementation of patient-derived xenograft (PDX) models reflecting diverse tumor heterogeneity for personalized oncology drug testing strategies
  • 5.5. Utilization of high-throughput in-vivo screening platforms to expedite lead compound optimization and reduce time to IND submission
  • 5.6. Expansion of GLP-compliant in-vivo CRO facilities in Asia-Pacific to meet the growing demand for regulatory-grade oncology data

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oncology Based In-Vivo CRO Market, by Animal Model

  • 8.1. Murine
    • 8.1.1. Genetically Engineered Mouse Model
    • 8.1.2. Immunocompetent Syngeneic
    • 8.1.3. Mouse Xenograft
  • 8.2. Non Murine
    • 8.2.1. Dog
    • 8.2.2. Rabbit
    • 8.2.3. Rat

9. Oncology Based In-Vivo CRO Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral
  • 9.3. Subcutaneous

10. Oncology Based In-Vivo CRO Market, by Therapeutic Modality

  • 10.1. Chemotherapy
  • 10.2. Immunotherapy
    • 10.2.1. Checkpoint Inhibitors
    • 10.2.2. Monoclonal Antibodies
  • 10.3. Targeted Therapy
    • 10.3.1. Kinase Inhibitors
    • 10.3.2. Small Molecule Inhibitors

11. Oncology Based In-Vivo CRO Market, by End User

  • 11.1. Academia & Research Institute
  • 11.2. Contract Research Organization
  • 11.3. Pharmaceutical

12. Oncology Based In-Vivo CRO Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Oncology Based In-Vivo CRO Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Oncology Based In-Vivo CRO Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Charles River Laboratories International, Inc.
    • 15.3.2. Laboratory Corporation of America Holdings
    • 15.3.3. WuXi AppTec Co., Ltd.
    • 15.3.4. Inotiv, Inc.
    • 15.3.5. Crown Bioscience, Inc.
    • 15.3.6. Taconic Biosciences, Inc.
    • 15.3.7. Pharmaron (Group) Co., Ltd.
    • 15.3.8. Explora BioLabs, Inc.
    • 15.3.9. GenScript ProBio Co., Ltd.
    • 15.3.10. Oncodesign SA

LIST OF FIGURES

  • FIGURE 1. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. ONCOLOGY BASED IN-VIVO CRO MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. ONCOLOGY BASED IN-VIVO CRO MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ONCOLOGY BASED IN-VIVO CRO MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY GENETICALLY ENGINEERED MOUSE MODEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY GENETICALLY ENGINEERED MOUSE MODEL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY GENETICALLY ENGINEERED MOUSE MODEL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY GENETICALLY ENGINEERED MOUSE MODEL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY GENETICALLY ENGINEERED MOUSE MODEL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY GENETICALLY ENGINEERED MOUSE MODEL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOCOMPETENT SYNGENEIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOCOMPETENT SYNGENEIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOCOMPETENT SYNGENEIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOCOMPETENT SYNGENEIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOCOMPETENT SYNGENEIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOCOMPETENT SYNGENEIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MOUSE XENOGRAFT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MOUSE XENOGRAFT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MOUSE XENOGRAFT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MOUSE XENOGRAFT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MOUSE XENOGRAFT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MOUSE XENOGRAFT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY DOG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY DOG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY DOG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY DOG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY DOG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY DOG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RABBIT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RABBIT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RABBIT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RABBIT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RABBIT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RABBIT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RAT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RAT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RAT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RAT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RAT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RAT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY KINASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY KINASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY KINASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY KINASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY KINASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ACADEMIA & RESEARCH INSTITUTE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ACADEMIA & RESEARCH INSTITUTE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ACADEMIA & RESEARCH INSTITUTE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ACADEMIA & RESEARCH INSTITUTE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ACADEMIA & RESEARCH INSTITUTE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ACADEMIA & RESEARCH INSTITUTE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY PHARMACEUTICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY PHARMACEUTICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY PHARMACEUTICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY PHARMACEUTICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 270. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 271. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 272. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 273. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2025-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2024 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2024 (USD MILLION)
  • TABLE 298. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2025-2032 (USD MILLION)
  • TABLE 299. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2024 (USD MILLION)
  • TABLE 300. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2025-2032 (USD MILLION)
  • TABLE 301. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2024 (USD MILLION)
  • TABLE 302. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2025-2032 (USD MILLION)
  • TABLE 303. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 304. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 305. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY T